Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christel Menet

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Immunology (Baltimore, Md. : 1950)|September 6, 2013
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseasesLuc Van Rompaey, René Galien, Ellen M van der Aar, et al.
Science Translational Medicine|February 15, 2023
IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseasesStéphanie Lavazais, Manja Jargosch, Sonia Dupont, et al.
Bioorganic & Medicinal Chemistry|October 24, 2024
Design of a potent and selective dual JAK1/TYK2 inhibitorOscar Mammoliti, Christel Menet, Céline Cottereaux, et al.
Nature Communications|October 1, 2024
Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonistThomas Fontaine, Andreas Busch, Toon Laeremans, et al.
Journal of Medicinal Chemistry|September 28, 2021
Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic DiseasesOscar Mammoliti, Koen Jansen, Sandy El Bkassiny, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Immunology (Baltimore, Md. : 1950)|September 6, 2013
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseasesLuc Van Rompaey, René Galien, Ellen M van der Aar, et al.
Science Translational Medicine|February 15, 2023
IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseasesStéphanie Lavazais, Manja Jargosch, Sonia Dupont, et al.
Bioorganic & Medicinal Chemistry|October 24, 2024
Design of a potent and selective dual JAK1/TYK2 inhibitorOscar Mammoliti, Christel Menet, Céline Cottereaux, et al.
Nature Communications|October 1, 2024
Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonistThomas Fontaine, Andreas Busch, Toon Laeremans, et al.
Journal of Medicinal Chemistry|September 28, 2021
Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic DiseasesOscar Mammoliti, Koen Jansen, Sandy El Bkassiny, et al.
Pageof 2